Sekar Kathiresan - 04 Jan 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: Chief Executive Officer, Director
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Issuer symbol: VERV
Transactions as of: 04 Jan 2022
Net transactions value: -$72,014
Form type: 4
Filing time: 06 Jan 2022, 15:36:22 UTC
Previous filing: 29 Dec 2021
Next filing: 15 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Options Exercise	$2,599	+1,870	+0.46%	$1.39^*	408,406	04 Jan 2022	Direct
transaction	VERV	Common Stock	Sale	$74,613	-1,870	-0.46%	$39.90	406,536	04 Jan 2022	Direct	F1
holding	VERV	Common Stock						80,997	04 Jan 2022	Kathiresan Family 2021 Irrevocable Trust
holding	VERV	Common Stock						80,997	04 Jan 2022	Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Stock Option (right to buy)	Options Exercise	$0	-1,870	-0.69%	$0.000000	267,425	04 Jan 2022	Common Stock	1,870	$1.39	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021.
F2	The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.